SEP 18, 2018 02:00 PM CEST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

POSTER: Development of Multiplex xMAP Technology-Based Assays for Simultaneous Detection of Soluble Checkpoint Molecules Involved in Anti-Cancer Immune Response

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Senior Manager, Research and Development, Antibodies and Immunoassays, Thermo Fisher Scientific
      Susanne received her PhD at the University of Vienna where she characterized the gene of a major cytoskeletal interlinking protein, plectin, which affects dynamic properties of the cytoskeleton and plays a role in tumor biology. Her postgraduate work focusing on chemotherapy resistance mechanisms in breast cancer cells was carried out at the Ludwig Bolzmann Institute of Clinical Experimental Oncology at the General Hospital in Vienna. Currently Suzanne is a senior scientist in the antibodies and immunoassays group in R&D at Thermo Fisher Scientific. She is a group leader in the multiplex immunoassays development team.


    To ensure the immune system’s balance between the recognition of non-self and the prevention of autoimmunity, the activity of immune cells needs to be strictly controlled. During the process of cancerogenesis, tumor cells try to resist immune responses and work to suppress the cycle of cancer immunity through multiple mechanisms involving regulatory proteins. These proteins—referred to as immune checkpoints—can affect immunoregulatory pathways by either boosting (co-stimulatory) or restricting (co-inhibitory) the immune response. For the majority of these checkpoint markers, soluble isoforms or shed variants that function as immune adjuvants or decoy receptors, have been identified. To date, cancer therapies that use antibodies targeted to the proteins within these immune checkpoint pathways have proven effective. It is also hypothesized that the measurement of the circulating concentration of the soluble forms of the immune checkpoint proteins could potentially correlate with the clinical efficacy of corresponding checkpoint modulator drugs.

    To test this hypothesis, we developed two comprehensive multiplexing panels (using Luminex® xMAP® technology) that are specifically designed to detect soluble checkpoint molecules involved in T cell and NK cell regulation. The panels allow the simultaneous detection of immune stimulatory and inhibitory factors, allowing a more holistic picture of the molecular players in cancer immunity. Preliminary results using the Invitrogen™ Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex™ Panel 1 (Cat. No. EPX14A-15803-901) and the Invitrogen™ Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex™ Panel 2 (Cat. No. EPX140-15815-901) demonstrate that there are different expression patterns for each that are dependent on both disease state and patient treatment. More in-depth analysis of these soluble biomarkers will hopefully shed more light on the biology of the immune checkpoint pathways and provide a possible tool for monitoring response to therapeutic treatment.

    Learning Objectives:

    • Investigate the advantage of using soluble checkpoint molecules as potential markers for the response to chemotherapy
    • Develop immunoassays for new immune regulating targets

    Show Resources
    Loading Comments...